Evidence map›Paper›PMID 38771342›Full record

ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2024

Tissue expression of miR-449a as risk factor for occult neck metastasis in patients with cT3-T4 N0 laryngeal cancer. A pilot study.

Filippo Ricciardiello, Michela Falco, Alfonso Scarpa, Giovanni Motta, Pasquale Viola, Marco Bocchetti, Michele Caraglia, Nello Alfieri, Flavia Oliva, Chiara Tammaro and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Filippo RicciardielloOtolaryngology Department, AORN Cardarelli, Naples, Italy.
Michela FalcoDepartment of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
Alfonso ScarpaDepartment of Medicine, Surgery and Dentistry, University of Salerno, Salerno, Italy.
Giovanni MottaDepartment of Mental, Physical Health and Preventive Medicine, University of Campania, "Luigi Vanvitelli", Naples, Italy.
Pasquale ViolaDepartment of Experimental and Clinical Medicine, Unit of Audiology, Regional Centre for Cochlear Implants and ENT Diseases, Magna Graecia University, Catanzaro, Italy.
Marco BocchettiDepartment of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
Michele CaragliaDepartment of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
Nello AlfieriDepartment of Anesthesia and Intensive Care, AORN Cardarelli, Naples, Italy.
Flavia OlivaOtolaryngology Department, AORN Cardarelli, Naples, Italy.
Chiara TammaroDepartment of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
Giuseppe TortorielloOtolaryngology Unit, AORN dei Colli, Monaldi Hospital, Naples, Italy.
Marco RadiciOtolaryngology Department, Fatebenefratelli Isola Tiberina, Gemelli Isola, Rome, Italy.
Angelo CamaioniOtolaryngology Department, San Giovanni-Addolorata Hospital, Rome, Italy.
Gabriella MissoDepartment of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
Pietro De LucaOtolaryngology Department, Fatebenefratelli Isola Tiberina, Gemelli Isola, Rome, Italy. dr.dlp@hotmail.it.ORCID http://orcid.org/0000-0002-6505-1680

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo explore the potential role of miR-449a as biomarker for laryngeal squamous cell carcinoma (LSCC), especially in the decision strategy of neck dissection (ND).

methodsEach patient underwent total laryngectomy and bilateral ND (levels II-IV); during surgery, tissue samples of around 1 × 0.5 cm were extracted from both healthy tissue adjacent to the tumor and the visibly affected tumor tissue. The extraction of total RNA, encompassing miRNA, was performed using a mirVana PARIS kit. To detect miR449a, cDNA was synthesized from 200 ng of RNA using a TaqMan miRNA reverse transcription kit.

resultsThe study group was formed of 66 patients (62 males, and 4 females) with LSCC, aged between 39 and 77 years (mean 60 + 14.56 yr). MiR-449a was up-regulated in twenty-eight tumors (42%), while it was down-regulated in 38 samples (58%). In the present study, there was a statistical relevance for miR-449a tissue expression for pN staging (p = 0.017), and PNI (p = 0.005). Eight tumors (12%) cN0 became pN + showing occult cervical lymph node metastases at the final histopathological examination, and all of these patients showed miR-449a downregulation.

conclusionSuper-selective ND (sparing the sub evels IIb and IV) might be the approach to cT3-T4 N0 LSCCs with upregulation of miR-449a; on the other hand, to ensure and effective control of occult neck metastases it would be appropriate to reserve elective ND (including sublevels IIb and IV) for cT3-T4 N0 LSCCs with miR-449a downregulation. Although promising, due to the small size of the cohort, the results of this work can be considered preliminary and need to be confirmed by prospective and larger studies.

Indexed as

Biomarkers, TumorCarcinoma, Squamous CellLaryngeal NeoplasmsLymphatic MetastasisMicroRNAsAdultAgedFemaleHumansLaryngectomyMaleMiddle AgedNeck DissectionNeoplasm StagingPilot ProjectsRisk FactorsBiomarkers, TumorMicroRNAsMIRN449 microRNA, humanLaryngeal cancerMiRNANeck dissectionSurgery

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.